Why anti-TNF drugs don't work for some kids with Crohn's disease - Medical Xpress

What To Know

Researchers analyzed pediatric trial samples to examine whether the HLA‑DQA1*05 genetic allele is linked to anti‑TNF treatment failure and development of anti‑drug antibodies in children with Crohn's disease. The study used samples from a prior multi‑center randomized trial comparing anti‑TNF alone versus anti‑TNF plus methotrexate.

HLA‑DQA1*05 was common in the group and was associated with higher rates of antidrug antibodies and treatment failure, while combination therapy with methotrexate was linked to lower failure rates.

The article reports the findings without overstating them: some associations were not statistically significant, and the authors describe potential clinical uses (targeted genetic screening) as something they are not yet doing universally.

It notes common clinical responses when anti‑TNF drugs stop working—dose escalation, adding methotrexate, or switching therapies—and highlights the lack of pediatric‑approved alternatives.

If validated in larger studies, HLA‑DQA1*05 testing might help guide decisions about using combination therapy or monitoring for antibodies in children starting infliximab or adalimumab. For now, the research suggests a promising direction but does not change standard care.